Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

Q Liu - Leukemia, 2016 - nature.com
Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that
has been extensively used as a tool compound to validate the role of BTK kinase in B cell …
被引用次数：38 相关文章

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

H Wu, C Hu, A Wang, EL Weisberg, W Wang… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML Ibrutinib selectively targets
FLT3-ITD in mutant FLT3-positive AML Leukemia. 2016 Mar;30(3):754-7. doi …
[HTML] nih.gov

[HTML][HTML] Ibrutinib Selectively Targets FLT3-ITD in Mutant FLT3-Positive AML

H Wu, C Hu, A Wang, EL Weisberg, W Wang, C Chen… - Leukemia, 2016 - ncbi.nlm.nih.gov
Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that
has been extensively used as a tool compound to validate the role of BTK kinase in B-Cell …

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

H Wu, C Hu, A Wang, E Weisberg, W Wang, C Chen… - Leukemia, 2016 - go.gale.com
Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that
has been extensively used as a tool compound to validate the role of BTK kinase in B cell …

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

H Wu, C Hu, A Wang, EL Weisberg, W Wang, C Chen… - Leukemia, 2015 - europepmc.org
Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that
has been extensively used as a tool compound to validate the role of BTK kinase in B-Cell …

[引用][C] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

H Wu, C Hu, A Wang, EL Weisberg, W Wang… - …, 2016 - kyushu-u.elsevierpure.com
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML — Kyushu University
Skip to main navigation Skip to search Skip to main content Kyushu University Home …

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

H Wu, C Hu, A Wang, EL Weisberg, W Wang, C Chen… - Leukemia, 2015 - europepmc.org
Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that
has been extensively used as a tool compound to validate the role of BTK kinase in B-Cell …

[引用][C] Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML

H Wu, C Hu, A Wang, EL Weisberg, W Wang… - …, 2016 - Nature Publishing Group